comparemela.com
  1. Home
  2. Live Updates
  3. Monotherapy - Breaking News

Page 8 - Monotherapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia

Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible StatusSEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage

United statesMiriam weber millerDirk huebnerJustin wattsExchange commissionAmerican society of hematologyAptevo therapeutics incUniversity of miami sylvester comprehensive cancer centerCombination armsAptevo therapeuticsAssociate professorLeukemia sectionMiami sylvester comprehensive cancer centerAmerican societySenior medical advisorOrphan drug

Aptevo Therapeutics : Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia

Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics. | March 29, 2022

United statesMiriam weber millerDirk huebnerJustin wattsExchange commissionAmerican society of hematologyAptevo therapeutics incUniversity of miami sylvester comprehensive cancer centerCombination armsAptevo therapeuticsAssociate professorLeukemia sectionMiami sylvester comprehensive cancer centerAmerican societySenior medical advisorOrphan drug

Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting

maximally sustaining IL-6 suppression in a chronic disease like NMOSD and enabling subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in. | March 25, 2022

United statesSouth koreaNathalie meetzLevi garrawayLoren kalmImpact of administration ocrelizumabSclerosis care centerDrug administrationHead of global product developmentRisdiplam clinical trial development programEuropean unionRoche groupAmerican academy of neurologyEuropean medicines agencyRoche group media relationsAmerican academy

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors

Open-label basket trial will assess the safety and efficacy of Zepzelca in patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination

United statesUnited kingdomArielle heekePharma marKristin bhavnaniAndrean flynnRob iannoneCommission file noJazz pharmaceuticalsHead of global corporate communicationsExchange commissionBritish thoracic oncology groupPrnewswire jazz pharmaceuticalsLevine cancer instituteAssociation of pulmonary pathologistsResponse evaluation criteria

Alkermes plc: Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium

- Data From ARTISTRY-1 Clinical Trial Highlight Single-Agent, Anti-Tumor Activity of Nemvaleukin in Patients With Renal Cell Carcinoma - DUBLIN, Feb. 17, 2022 /PRNewswire/ Alkermes

United statesEmiliano calvoCraig hopkinsonSandy coombsSourojit bhowmickAmerican society of clinical oncologyResearch development at alkermesMerck sharp dohme corpExchange commissionNemvaleukin clinical development programMerck co incClinical researchTrial highlight single agentAnti tumor activityPatients with renal cell carcinomaAmerican society

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.